<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912596</url>
  </required_header>
  <id_info>
    <org_study_id>TW20-4643</org_study_id>
    <nct_id>NCT04912596</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma</brief_title>
  <official_title>A Randomized, Single-dose, Double-blind, Double-dummy, Placebo and Active Controlled, Crossover Design Study Using Bronchoprovocation to Evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intech Biopharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intech Biopharm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of&#xD;
      albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal&#xD;
      to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA [albuterol&#xD;
      sulfate] Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation&#xD;
      manufactured by two different manufacturers using methacholine bronchoprovocation challenge&#xD;
      test in patients with stable mild asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-dose PC20 Concentration</measure>
    <time_frame>15 minutes post-dose</time_frame>
    <description>Post-dose PC20, which are the provocative concentrations, respectively, of the methacholine challenge agent required to reduce the forced expiratory volume in one second (FEV1) by 20% following administration of differing concentrations of albuterol (or placebo) by inhalation.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mild Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two different Reference Placebo inhalers and two different Test Placebo inhalers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two different Reference inhalers and two different Test Placebo inhalers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Sulfate inhalation aerosol 108 mcg per actuation</intervention_name>
    <description>eq. to albuterol 90 mcg/puff, MDI</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg per actuation</intervention_name>
    <description>eq. to albuterol 90 mcg/puff, MDI</description>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_label>Reference 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Proair HFA Inhalation Placebo</intervention_name>
    <description>MDI</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Albuterol Sulfate inhalation Placebo</intervention_name>
    <description>MDI</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Methacholine</intervention_name>
    <description>Methacholine 100 mg/vial</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, non-pregnant and non-lactating female subjects (20-65 years of age, inclusive).&#xD;
&#xD;
          2. A clinical diagnosis of mild asthma with historical documentation of the asthma&#xD;
             diagnosis according to either: (1) the National Asthma Education and Prevention&#xD;
             Program (NAEPP) guidelines; (2) the Global Initiative for Asthma (GINA) Global&#xD;
             Strategy for Asthma Management and Prevention.&#xD;
&#xD;
          3. Stable mild asthma receiving one of the following required inhaled medication for at&#xD;
             least 1 month prior to screening: (1) only short-acting beta-agonists (SABA) used&#xD;
             as-needed; (2) low doses of ICS (as allowed in the ICS Table in Section 9.1.1, alone&#xD;
             or in combination with SABA) used regularly with a stable regimen&#xD;
&#xD;
          4. Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of predicted after withholding SABA&#xD;
             ≥ 8 hours.&#xD;
&#xD;
          5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline)&#xD;
             PC20 ≤ 8 mg/mL.&#xD;
&#xD;
          6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5&#xD;
             pack-years (the equivalent of one pack per day for 5 years).&#xD;
&#xD;
          7. Provision of written informed consent.&#xD;
&#xD;
          8. Other than asthma, in general good health.&#xD;
&#xD;
          9. Body mass index (BMI) between 17 and 35 kg/m2 (inclusive).&#xD;
&#xD;
         10. Able to correctly use MDI inhalers.&#xD;
&#xD;
         11. Able to perform valid and reproducible pulmonary function tests including no evidence&#xD;
             of spirometry effort-induced bronchoconstriction.&#xD;
&#xD;
         12. If the subject or subject's partner is of child-bearing potential, a medically&#xD;
             acceptable form of contraception will be used for the duration of the study. Medically&#xD;
             acceptable contraceptives include: (1) surgical sterilization, (2) Health Authority&#xD;
             approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms&#xD;
             with spermicide, or (5) diaphragm with spermicide.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of conditions altering airway reactivity to methacholine, including upper or&#xD;
             lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic&#xD;
             rhinitis, sinobronchitis, etc.) within 6 weeks before Screening.&#xD;
&#xD;
          2. History of seasonal asthma exacerbations, in which case the subject should be studied&#xD;
             outside of the relevant allergen season.&#xD;
&#xD;
          3. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseases&#xD;
             including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma,&#xD;
             pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator,&#xD;
             would compromise subject safety or interfere with the evaluations.&#xD;
&#xD;
          4. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric,&#xD;
             endocrine dysfunction, including ECG with evidence of ischemic heart diseases and&#xD;
             significant arrhythmias.&#xD;
&#xD;
          5. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within&#xD;
             3 months prior to screening.&#xD;
&#xD;
          6. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2&#xD;
             receptor-agonist drug, HFA, any related compounds or methacholine.&#xD;
&#xD;
          7. Need for daily oral corticosteroids within 3 months prior to screening.&#xD;
&#xD;
          8. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in the&#xD;
             opinion of the Investigator would compromise subject safety or interfere with the&#xD;
             evaluations, or a QTc &gt; 440 ms for males and &gt; 460 ms for females using Fredericia&#xD;
             formula.&#xD;
&#xD;
          9. Subjects receiving beta blocker via any route or who may require beta blockers during&#xD;
             the study.&#xD;
&#xD;
         10. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled&#xD;
             diabetes, paradoxical bronchospasm&#xD;
&#xD;
         11. History of malignancies&#xD;
&#xD;
         12. History of alcohol or drug abuse&#xD;
&#xD;
         13. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening.&#xD;
&#xD;
         14. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton,&#xD;
             theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening.&#xD;
&#xD;
         15. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinic&#xD;
             antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE,&#xD;
             anti-IL5/5R, anti-IL4R, high dose ICS (as listed in the Inhaled Corticosteroid Table&#xD;
             in Section 9.1.1), or systemic corticosteroid for treatment of asthma within 6 months&#xD;
             prior to screening.&#xD;
&#xD;
         16. Known Human Immunodeficiency Virus (HIV)-positive status.&#xD;
&#xD;
         17. Participated in any interventional clinical trials within 1 month prior to screening.&#xD;
&#xD;
         18. Pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabina Chien</last_name>
    <phone>+886-908-406881</phone>
    <email>sabina.i198@intechbiopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit,Mackay Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

